Probiotic Bacillus subtilis Protects against -Synuclein Aggregation in C. elegans

Citation for published version:
Goya, ME, Xue, F, Sampedro-torres-quevedo, C, Arnaouteli, S, Riquelme-dominguez, L, Romanowski, A, Brydon, J, Ball, KL, Stanley-wall, NR & Doitsidou, M 2020, ‘Probiotic Bacillus subtilis Protects against -Synuclein Aggregation in C. elegans’, Cell Reports, vol. 30, no. 2, pp. 367-380.e7.
https://doi.org/10.1016/j.celrep.2019.12.078

Digital Object Identifier (DOI):
10.1016/j.celrep.2019.12.078

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Cell Reports

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Probiotic *Bacillus subtilis* Protects against α-Synuclein Aggregation in *C. elegans*

**Graphical Abstract**

**Highlights**

- *B. subtilis* PXN21 inhibits and reverses α-syn aggregation in a *C. elegans* model

- Spores and vegetative cells protect through different mechanisms

- The probiotic inhibits α-syn aggregation by changing the host sphingolipid metabolism

- Biofilm formation in the gut and bacterial metabolites reduce α-syn aggregation

**In Brief**

How the gut microbiome affects Parkinson’s disease remains unclear. Goya et al. show that the probiotic *B. subtilis* strain PXN21 inhibits and clears α-synuclein aggregation in a *C. elegans* model. The bacterium acts via metabolites and biofilm formation to activate protective pathways in the host, including DAF-16/FOXO and sphingolipid metabolism.

**Authors**

María Eugenia Goya, Feng Xue, Cristina Sampedro-Torres-Quevedo, ..., Kathryn L. Ball, Nicola R. Stanley-Wall, Maria Doitsidou

**Correspondence**

maria.doitsidou@ed.ac.uk

---

Goya et al., 2020, Cell Reports 30, 367–380
January 14, 2020 © 2019 The Author(s).
https://doi.org/10.1016/j.celrep.2019.12.078
Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans

Maria Eugenia Goya,1 Feng Xue,1,5 Cristina Sampedro-Torres-Quevedo,1,5 Sofia Arnaouteli,2 Lourdes Riquelme-Dominguez,1 Andrés Romanowski,3 Jack Brydon,4 Kathryn L. Ball,4 Nicola R. Stanley-Wall,2 and Maria Doitsidou1,6,*

1University of Edinburgh, Centre for Discovery Brain Sciences, Edinburgh, Scotland
2University of Dundee, School of Life Sciences, Dundee, Scotland
3University of Edinburgh, School of Biological Sciences, Edinburgh, Scotland
4University of Edinburgh, Institute of Genetics & Molecular Medicine, Edinburgh, Scotland
5These authors contributed equally
6Lead Contact
*Correspondence: maria.doitsidou@ed.ac.uk
https://doi.org/10.1016/j.celrep.2019.12.078

SUMMARY

Recent discoveries have implicated the gut microbiome in the progression and severity of Parkinson’s disease; however, how gut bacteria affect such neurodegenerative disorders remains unclear. Here, we report that the Bacillus subtilis probiotic strain PXN21 inhibits α-synuclein aggregation and clears preformed aggregates in an established Caenorhabditis elegans model of synucleinopathy. This protection is seen in young and aging animals and is partly mediated by DAF-16. Multiple B. subtilis strains trigger the protective effect via both spores and vegetative cells, partly due to a biofilm formation in the gut of the worms and the release of bacterial metabolites. We identify several host metabolic pathways differentially regulated in response to probiotic exposure, including sphingolipid metabolism. We further demonstrate functional roles of the sphingolipid metabolism genes lagr-1, asm-3, and sptl-3 in the anti-aggregation effect. Our findings provide a basis for exploring the disease-modifying potential of B. subtilis as a dietary supplement.

INTRODUCTION

Protein misfolding and aggregation are key pathological features observed in numerous neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease (PD) (Ross and Poirier, 2004). PD is one of the most prevalent neurodegenerative disorders (Pringsheim et al., 2014) and is currently incurable. It is characterized by the progressive loss of dopaminergic neurons in the Substantia Nigra area of the brain, leading to the development of progressive motor and non-motor symptoms (Poewe et al., 2017). Central to the condition is the accumulation of α-synuclein (α-syn) aggregates in Lewy bodies (Spillantini et al., 1998), and the extent of this accumulation correlates with disease severity (Stefanis, 2012), α-syn acquires neurotoxic properties when protein monomers progressively combine to form insoluble amyloid fibrils via oligomeric intermediates (Poewe et al., 2017). Although Lewy bodies contain mostly fibrillar forms of α-syn, oligomeric intermediates are also toxic and play a central role in PD pathogenesis (Winner et al., 2011). Despite recent progress toward identifying disease-modifying interventions (Savitt and Jankovic, 2019), only symptomatic treatments are available (Fahn, 2015). Thus, therapeutic strategies directed at inhibiting or reversing α-syn aggregation present a clear opportunity for disease-modifying interventions for PD and other synucleinopathies.

Although PD is primarily considered to be a central nervous system disease, there is clear evidence for an involvement of peripheral signals, particularly from the gastrointestinal tract and the gut microbiota, in PD progression. This is supported by observations that PD symptoms and α-syn pathology begin in peripheral tissues, particularly the intestine, and as the disease progresses, α-syn aggregates gradually spread to multiple brain regions (Braak et al., 2003; Rietdijk et al., 2017). Recently, the human gut microbiome has emerged as an important player influencing PD (Schepersjans, 2016). Gut bacteria can affect brain function by producing metabolites that enter the bloodstream, eliciting immune responses in the host or modulating neuronal function (Chow et al., 2010; Fung et al., 2017). Preclinical evidence suggests that the gut microbiota and intestinal permeability modulate behavior, mood, and neuropsychiatric disorders (Clapp et al., 2017). Likewise, a large number of recent studies investigating microbiota in patients with PD found notable differences compared to healthy controls (reviewed by Boertien et al., 2019), which correlated with clinical features (Li et al., 2017; Minato et al., 2017; Schepersjans et al., 2015). Remarkably, faecal transplants from PD patients exacerbate symptoms in a mouse model of PD, demonstrating that differences in microbiota are not merely a result of the disease, but also impact its progression (Sampson et al., 2016).

Human microbiota consist of trillions of microorganisms and over 1,000 bacterial species (Lloyd-Price et al., 2016), posing a challenge for understanding the effects of individual species. In
the bacterivore Caenorhabditis elegans, the gut microbiota can be precisely controlled, making it a powerful model for studying the effects of gut bacteria on physiological processes at a single species-single gene level (Cabreiro and Gems, 2013). Furthermore, C. elegans has proven to be a valuable model for studying molecular mechanisms of PD and protein aggregation. Overexpression of human α-syn in C. elegans results in the formation of aggregates that progressively become amyloid-like (Kaminski Schierle et al., 2011; van Ham et al., 2008), and work in C. elegans models has identified conserved genetic and chemical modifiers of α-syn toxicity (Böttner et al., 2013; Hamamichi et al., 2008; Kautu et al., 2013; Knight et al., 2014; Kuwahara et al., 2008; Pujols et al., 2018; Qiao et al., 2008; Roozveldt et al., 2009; Ruan et al., 2010; van Ham et al., 2008; Zhang et al., 2017). Here, we used a C. elegans model of synucleinopathy to investigate the effects of gut bacteria on α-syn aggregation.

We report that the probiotic bacterium Bacillus subtilis PXN21 (Colenutt and Cutting, 2014), when fed to C. elegans, inhibits, delays, and reverses α-syn aggregation. We characterize these protective effects in both young and old nematodes and investigate the contributions of known lifespan-extending pathways. We further show that B. subtilis extracts are able to partially recapitulate the protective effect of live bacteria, indicating that a bacterial metabolite is actively involved. From analysis of gene expression profiles, we find that the protective effect of B. subtilis against α-syn aggregation is mediated through alterations in the sphingolipid metabolism pathway. Our findings contribute to the current understanding of how gut bacteria interact with the host to influence physiology in remote tissues, and they will motivate further explorations of the probiotic B. subtilis as a diet-based intervention for PD.

RESULTS

B. subtilis Inhibits and Reverses α-Syn Aggregation in a C. elegans Model of Synucleinopathy

To assess the effect of gut bacteria on α-syn aggregation, we used an established C. elegans model (strain NL5901), expressing human α-syn fused to yellow fluorescent protein (YFP) and driven by a muscle-specific promoter (Punc-54::α-syn::YFP) (van Ham et al., 2008). We fed these worms with different bacterial diets and assessed α-syn aggregation in day 1 adult animals (72 h post hatching). Among the bacterial species tested was the B. subtilis strain PXN21 (Colenutt and Cutting, 2014), isolated from the commercially available probiotic product Bio-Kult (by ADM Protexin).

On a regular C. elegans laboratory diet, comprising the non-pathogenic strain of Escherichia coli OP50 (Brenner, 1974), α-syn-expressing animals formed aggregates that can be visualized by fluorescence microscopy (van Ham et al., 2008) (Figures 1A and 1B). In contrast, animals fed on B. subtilis strain PXN21 showed a nearly complete absence of aggregates at the day 1 adult stage (Figures 1A and 1B). This striking difference in aggregation was not caused by lower expression levels of α-syn in PXN21-fed animals, as unc-54 and α-syn transcript levels were upregulated in day 1 adult animals fed with B. subtilis (Figure 1C). Consistently, there were higher levels of α-syn protein in animals fed on the probiotic (Figures 1D and S1A).

We next tested whether a B. subtilis diet could also clear already-formed aggregates. We grew nematodes on E. coli until the fourth larval (L4) stage when aggregates are evident, then shifted them to a B. subtilis PXN21 diet (Figure 1E) and quantified α-syn aggregation and protein in animals (Figure 1F). The clearance of aggregates was not due to reduced levels of α-syn expression (Figures S1D–S1F). Notably, the reduced aggregation levels after the switch to B. subtilis persisted for longer, compared to animals grown continuously on this diet from the first larval (L1) stage (Figure 1G). Similar results were obtained in experiments where the food switch happened on the first day of adulthood (Figures S1G and S1H). We further investigated α-syn native forms using non-denaturing gel electrophoresis. Whereas high molecular mass α-syn forms were detected in extracts from worms ingesting either diet, lower molecular weight species that go down to a submonomeric form were primarily detected with the B. subtilis diet (Figure 1H). This indicates alterations of α-syn forms, possibly through cleavage or degradation, by this dietary condition.

B. subtilis Protection Is Effective throughout C. elegans Aging

To assess the effects of a B. subtilis diet on α-syn aggregation in aging, we followed animals fed on E. coli OP50 or B. subtilis PXN21 until day 13 of adulthood (corresponding to day 16 of the worm’s life). We assessed aging animals under two different feeding conditions: (1) grown continuously on the specified diet for their entire life or (2) grown on E. coli until the L4 stage and then shifted to a B. subtilis diet. When C. elegans were grown continuously on E. coli after hatching, aggregates were observed as early as the second larval (L2) stage (data not shown) and progressively increased in number up to day 3 of adulthood (Figure 2A). In contrast, in animals continuously grown on B. subtilis PXN21, there was a near-complete absence of aggregation until day 1 of adulthood, followed by a delayed increase in the number of foci up to day 5 and a subsequent decline. The maximum number of aggregates reached in animals fed with B. subtilis was far lower than that observed on the E. coli diet, indicating that B. subtilis does not simply delay aggregate formation.

In the second feeding condition, when worms were switched from the E. coli to the B. subtilis diet at the L4 stage, aggregation dropped rapidly, reaching a very low, steady level until day 13 of adulthood (Figure 2B). To test whether the reduction of aggregation had an impact on the fitness of α-syn-expressing animals, we performed locomotion assays in a liquid medium. The locomotion fitness of C. elegans was significantly improved after the switch to the B. subtilis diet, compared to animals continuously fed on E. coli, for a time interval that mirrored the time of reduced aggregation (Figure 2C). We conclude that the most striking effect on aggregation is conferred during continuous growth on B. subtilis, with nearly no foci in day 1 of adulthood, whereas the most long-lasting effect is achieved after switching to a B. subtilis diet, with aggregation levels remaining low throughout mid- and late adulthood.
The *B. subtilis* diet inhibits aggregation during aging without reducing the expression of α-syn, compared to the *E. coli* diet (Figures 2D and 2E). The decline in aggregation in older *E. coli*-fed worms correlates with the age-dependent decrease in the expression of the unc-54 promoter (Budovskaya et al., 2008) and, consequently, in α-syn protein levels (Figures 2D and 2E). Remarkably, this decrease is more pronounced in aging worms fed on *E. coli* (Figure 2E), in agreement with previous reports showing a differential diet-dependent regulation of unc-54 expression (Sánchez-Blanco et al., 2016). Thus, *B. subtilis* inhibits aggregation in aging worms despite the consistently higher levels of α-syn in this diet relative to *E. coli*.

The Protective Effect against α-Syn Aggregation Is a General Property of *B. subtilis* Species

Previous studies report stress resistance and longevity benefits for wild-type animals grown on various laboratory *B. subtilis* strains (Donato et al., 2017; Garsin et al., 2003; Gusarov et al., 2013; Smolentseva et al., 2017). We therefore asked whether the observed effect on α-syn aggregation is unique to PXN21 or if it is shared among other strains of the *B. subtilis* species. We tested a panel of laboratory *B. subtilis* strains, including 168 (Zeigler et al., 2008), JH642 (Smith et al., 2014), and the un-domesticated strain NCIB 3610 (Branda et al., 2001). All strains showed similar effects on α-syn aggregation to the probiotic strain PXN21 following the continuous or food-switching regime (Figures 2F and 2G), indicating that the anti-aggregation effect is a general property of the *B. subtilis* species. Furthermore, all tested *B. subtilis* strains extended the lifespan of α-syn-expressing transgenic animals (Figure 2H; Table S1).

**B. subtilis** Biofilm Formation and Nitric Oxide Production Protect from α-Syn Aggregation in Aging

*B. subtilis* was previously shown to increase lifespan and stress tolerance in *C. elegans* via several partly co-dependent mechanisms: the formation of a biofilm, a three-dimensional bacterial community embedded in a self-produced extracellular matrix (Branda et al., 2005), in the gut of day 7 adult worms (Donato...
et al., 2017; Smolentseva et al., 2017); the production of nitric oxide (NO) (Gusarov et al., 2013); and the secretion of colony-stimulating factor (CSF) quorum-sensing pentapeptide (Donato et al., 2017). We first confirmed that the yet-uncharacterized B. subtilis strain PXN21 was very proficient at forming a hydrophobic biofilm under standard conditions, similar to the well-characterized B. subtilis NCIB 3610 (Figure S2A).

To explore whether any of the above bacterial pathways regulating lifespan and stress resistance in C. elegans were also responsible for reducing α-syn aggregation in our model, we applied the food-switching approach with B. subtilis NCBI 3610 alongside the biofilm-deficient derivatives Jeps(A-O), ΔbslA, and ΔtasA (Figure S2A). Each of these strains lacks a different extracellular matrix component essential for biofilm formation: Jeps(A-O) is defective in exopolysaccharide formation (Branda et al., 2001); ΔtasA lacks protein fibers (Romero et al., 2010); and ΔbslA is deficient in forming the hydrophobic surface layer that surrounds the biofilm (Hobley et al., 2013; Kobayashi and Iwano, 2012). We found no effect of biofilm mutations on aggregation in the early days of adulthood (Figures 3A and S2B). In contrast, after day 5 of adulthood, when biofilms form in the gut of the nematodes, α-syn aggregation progressively increased when animals were fed the ΔtasA strain, but not the Jeps(A-O) or ΔbslA deletion strains (Figures 3A and S2B). The triple-mutant strain combining all three biofilm deletions (ΔJeps(A-O), ΔtasA, and ΔbslA) did not further increase aggregation. We conclude that the biofilm matrix protein TasA supports the ability of B. subtilis to protect against α-syn aggregation later in adulthood.

Similar to the ΔtasA biofilm-deficient strain, deletion strains for ΔphrC, defective in the production of the quorum-sensing pentapeptide CSF, and Δnos, defective in NO production, also showed an increase in aggregates later in adulthood but not in earlier stages when compared to the wild-type strain (Figures 3B and S2C). These results are in agreement with previous reports that NO and CSF production is increased by an order of magnitude under biofilm-forming conditions (Donato et al., 2017).

Given that the ΔphrC and Δnos deletion results implicate CSF and NO in the prolonged protective effect of B. subtilis against α-syn aggregation, we asked whether exogenous supplementation of these metabolites in the absence of biofilm could exert a protective effect earlier in adulthood. Whereas animals grown on E. coli supplemented with CSF showed no changes in aggregation under the tested conditions (data not shown), NO directly supplied to the worm’s diet induced a significant reduction of...
aggregation on day 3 of adulthood (Figure 3C). In summary, biofilm-associated bacterial pathways/metabolites responsible for lifespan extension are required for keeping aggregation levels low during aging; however, they do not explain the strong protection observed in early adults.

### A Bacterial Metabolite from B. subtilis Inhibits α-Syn Aggregation in Early Adults

Stress resistance and longevity effects induced by B. subtilis in C. elegans were shown to require live bacteria colonizing the nematode’s gut (Donato et al., 2017; Garsin et al., 2003; Gusarov et al., 2013; Smolentseva et al., 2017). In our case, these mechanisms seem to be relevant only for the effect of B. subtilis against α-syn aggregation in late adulthood and cannot explain the strong protection seen in early adulthood, when no biofilm is present and only insufficient levels of NO are likely available from ingested B. subtilis. To address whether the effects of B. subtilis in early adulthood required live bacteria, we fed α-syn-expressing worms dead B. subtilis, killed by a combination of UV and antibiotics. Surprisingly, dead B. subtilis were as protective as live bacteria at day 1 of adulthood (Figure 3D).

We next considered whether we could recapitulate the protective effect in the absence of bacteria by supplementing the worms’ diet with B. subtilis extracts. Nematodes grown from the L1 on an E. coli diet supplemented with B. subtilis crude extracts from either the supernatant or pelleted vegetative cells showed a 17%–21% and 21%–33% reduction in aggregation, respectively (Figures 3E and 3F). Therefore, the effect of B. subtilis on α-syn aggregation in early adults is partially mediated by the action of an active and stable bacterial metabolite, unlike the short-lived NO, associated with the suppression of aggregation later in life.

### B. subtilis Spores and Vegetative Cells Both Protect against α-Syn Aggregation

Bacterial metabolic state is affected by environmental conditions and can strongly influence bacteria-host interactions. B. subtilis can exist in two distinct metabolic states: (1) as metabolically active, dividing vegetative cells in nutrient-rich conditions, and (2) as dormant, environmentally resistant spores in nutrient-poor or hostile environments (Nicholson and Setlow, 1990). Under our regular experimental conditions, B. subtilis forms lawns that contain a mix of spores and vegetative cells (Figure S3A). Both forms were previously shown to confer longevity and stress-resistance benefits in C. elegans via distinct mechanisms (Donato et al., 2017; Gusarov et al., 2013; Sánchez-Blanco et al., 2016; Smolentseva et al., 2017).

To determine whether the effect of B. subtilis PXN21 on α-syn aggregation depends on the presence of either spores or vegetative cells, we used selective media to acquire pure cultures of each state (see Method Details and Figure S3A). We found that both B. subtilis vegetative cells and spores fully prevented aggregation in day 1 adult worms, similar to the mixed lawns (Figures 4A and 4B), and both reversed preformed aggregates.
We corroborated the protective effect of *B. subtilis* vegetative cells in early adulthood using the strain 168 carrying a deletion in the spoIIE gene, required for sporulation (York et al., 1992). α-syn expressing animals grown on vegetative cells of 168 ΔspoIIE strain showed similar levels of aggregation, compared to those grown on vegetative cells of the wild-type *B. subtilis* strain 168 (Figures 4D and S3F).

Finally, we assessed the effect of vegetative cells of *B. subtilis* PXN21 on α-syn aggregation during aging. Worms grown continuously on vegetative cells showed a general delay in the formation of aggregates, but the number of aggregates eventually reached a maximum comparable to that of worms grown on vegetative cells of the wild-type *B. subtilis* strain 168 (Figures 4D and S3F).

We first considered that DR may underlie the specific protective effects of spores against aggregation, as *C. elegans* is virtually unable to digest spores (Laaberki and Dworkin, 2008) (Figures 5A and S4A). A *B. subtilis* spores-only diet poorly sustained growth, inducing severe signs of DR, which is reflected by a strong delay in development to adulthood by 5–7 days and a significantly smaller size in adult worms, compared to those grown on vegetative cells of the wild-type *B. subtilis* strain 168 (Figures 4D and S3F).

Finally, we assessed the effect of vegetative cells of *B. subtilis* PXN21 on α-syn aggregation during aging. Worms grown continuously on vegetative cells showed a general delay in the formation of aggregates, but the number of aggregates eventually reached a maximum comparable to that of worms grown on *E. coli* (Figure 4E). In contrast, when worms were shifted at the L4 stage from *E. coli* to a *B. subtilis* lawn of vegetative cells, the aggregation levels remained low until late in adulthood (Figure 4F), similar to those of a mixed lawn diet (Figure 2B).

As both vegetative cells and spores are protective, we next investigated whether they protect through similar or different mechanisms, focusing first on the known lifespan-extending pathways, dietary restriction (DR), and the insulin-like signaling (ILS) pathway.

**Spores Induce DR and Vegetative Cells Protect via a DR-Independent Mechanism**

We first considered that DR may underlie the specific protective effects of spores against aggregation, as *C. elegans* is virtually unable to digest spores (Laaberki and Dworkin, 2008) (Figures 5A and S4A). A *B. subtilis* spores-only diet poorly sustained growth, inducing severe signs of DR, which is reflected by a strong delay in development to adulthood by 5–7 days and a significantly smaller size in adult worms, compared to those grown on *E. coli* (Figure 4B). Worms grown on mixed *B. subtilis* lawns showed mild DR, manifested by a slight developmental delay and smaller body size compared to those grown on *E. coli* (Figures 5A–5C, S4B, and S4C). In contrast, worms fed only with vegetative cells did not show any signs of DR (Figures 5A–5C, S4B, and S4C). In addition, only small brood size differences between the two diets were observed, which disappeared in the food-switching condition (Figures S4D–S4G). This rules out diet effects on fecundity as a contributing factor to the reduction of aggregation.

(Figures 4C and S3B). The reduced aggregation on the vegetative cell diet was not due to lower α-syn expression (Figures S3C–S3E).
**Figure 5. B. subtilis Reduces α-Syn Aggregation through Dietary-Restriction-Dependent and Independent Mechanisms**

(A) Fluorescent images of α-syn worms fed on transgenic NCIB 3610 B. subtilis expressing amyE:Phyper-spank-mKate2. Spores resistant to digestion can be seen in the entire gut in red (left); vegetative cells are present only before the pharyngeal grinder (right).

(B and C) Developmental stage at 48 h (B) and body size at 72 h (C) of α-syn-expressing worms grown on E. coli or B. subtilis mixed-cell lawns or vegetative cells. 

(D) Normalized pha-4 expression level in young adult worms grown on the different diet conditions. pha-4 expression in worms fed with E. coli was taken as 1. **p = 0.0059; n = 3 samples per condition, with three technical replicates each (each sample consisting of ~4,000 worms).

(E) Quantification of α-syn aggregates in day 1 adult worms fed on E. coli, B. subtilis, or a 1:1 mixture (B. subtilis: E. coli). ***p < 0.0001; n = 25 worms per condition.

(F) Quantification of α-syn aggregates per animal of wild-type or eat-2(ad456) worms grown on E. coli or B. subtilis mixed-cell lawn. **p < 0.0001; n = 75 worms per time point per condition from three independent experiments.

(G) Normalized pha-4 expression levels by qRT-PCR of young adult worms grown on the diet conditions shown in (F). **p = 0.0096; n = 3 samples per condition, with three technical replicates each (each sample consisting of ~4,000 worms).

(H) Quantification of α-syn aggregates of day 1 adult worms fed on low concentrations of freshly alive or UV-killed E. coli. ****p < 0.0001, n = 25 worms per condition.

(I) Average α-syn aggregates of worms before and after L4 switching to E. coli, B. subtilis mixed lawns, or UV-killed E. coli 48 h after seeding. L4, larval stage 4; d1ad, day 1 adult; d3ad, day 3 adult. ***p < 0.0001 comparison versus E. coli; a versus b, ns for E. coli to UV-killed E. coli versus E. coli versus, ****p < 0.0001 for E. coli to B. subtilis versus E. coli; n = 25 worms per time point per condition. Data shown are mean ± SEM from one representative experiment out of three with similar results, unless stated otherwise. ns, no significant differences.

We confirmed that B. subtilis mixed lawns induced a state of DR using the marker pha-4, an ortholog of the FoxA transcription factors (Panowski et al., 2007); there was a significant increase in pha-4 levels in animals fed on mixed B. subtilis lawns, but not on vegetative cells, compared to animals grown on E. coli (Figure 5D). Furthermore, when we supplemented B. subtilis mixed lawns with E. coli at a 1:1 ratio, we saw a strong protection against α-syn aggregation (Figure 5E) in the absence of pha-4 upregulation (Figure 5D). These results suggest that DR is not responsible for the anti-aggregation effect of vegetative cells, but it may have an effect when animals are fed on spore-rich lawns.

DR was previously shown to suppress proteotoxicity in animal models of polyglutamine and amyloid beta aggregation (Steinkraus et al., 2008), to modify adverse effects of α-syn on the autonomic nervous system in mice (Griffioen et al., 2013), and to alleviate α-syn toxicity in yeast (Guedes et al., 2017). However, to our knowledge, no direct evidence exists that DR can inhibit α-syn aggregation in animal models. We therefore tested whether loss of function of the nicotinic acetylcholine receptor subunit eat-2, a genetic mimic of dietary restriction due to reduced food uptake (Lakowski and Hekimi, 1998; McKay et al., 2004), was able to suppress α-syn aggregate formation. Indeed, eat-2(ad456) animals grown on E. coli showed less aggregation in day 1 and day 3 adults, compared to wild-type animals grown on E. coli (Figure 5F). However, this reduction was much weaker than the one seen in worms grown on B. subtilis mixed lawns. In addition, a B. subtilis diet further decreased the number of aggregates of eat-2 mutants (Figure 5F), without further increasing pha-4 expression levels (Figure 5G). Similar effects were obtained with a B. subtilis vegetative cell diet (Figures S4H and S4I).

We further confirmed that DR is able to inhibit α-syn aggregation by feeding worms with limited amounts of E. coli killed by UV, a known experimental way to induce DR in C. elegans (Greer et al., 2007) (Figures 5H, S4J, and S4K). However, shifting worms fed ad libitum on E. coli until the L4 stage (or until day 1 of adulthood) to a DR-inducing UV-killed E. coli condition did not clear preformed aggregates (Figures 5I and S4L), even though it inhibited the formation of new aggregates like the probiotic...
diet (Figure 5I). Therefore, DR per se does not fully reproduce the sum of \( B. \text{subtilis} \) effects, which include both inhibition and the clearance of aggregates.

Together, these results reveal that DR has a protective role against \( \alpha \)-syn aggregation, and it may underlie part of the protective effect triggered by \( B. \text{subtilis} \) spores. However, vegetative cells inhibit and dissolve \( \alpha \)-syn aggregates through a DR-independent mechanism.

**DAF-16 Contributes to the Protection of \( B. \text{subtilis} \) Later in Adulthood**

A *C. elegans* lifespan extension by \( B. \text{subtilis} \) was previously linked to the downregulation of the evolutionarily conserved ILS pathway (Donato et al., 2017). Decreased signaling of the insulin growth factor (IGF) receptor DAF-2 (Kenyon et al., 1993; Kimura et al., 1997) extends lifespan by activating two downstream transcription factors, DAF-16/FOXO (Lin et al., 1997; Ogg et al., 1997) and HSF-1 (Hsu et al., 2003). A reduced ILS also protects worms from stress conditions such as toxic protein aggregation of polyglutamine stretches (Hsu et al., 2003; Morley et al., 2002), amyloid beta (Cohen et al., 2006), and \( \alpha \)-syn (Knight et al., 2014). To determine whether the ILS pathway plays a role in the \( B. \text{subtilis} \)-triggered protection against \( \alpha \)-syn aggregation, we used \( daf-2(e1370) \) mutant worms with inhibited ILS signaling (Gems et al., 1998). The \( daf-2(e1370) \) \( \alpha \)-syn-expressing animals grown on *E. coli* showed a strong suppression of aggregates in day 1 and day 3 adults compared to wild-type animals (Figure 6A), confirming previous reports (Knight et al., 2014). However, the \( daf-2 \) protective effect was significantly less pronounced than that seen in *B. subtilis* PXN21-fed wild-type worms, and the *B. subtilis* diet further reduced aggregation levels of \( daf-2(e1370) \) animals (Figure 6A). The additive effect between the *B. subtilis* diet and \( daf-2 \) downregulation indicates that *B. subtilis* acts through an ILS-independent pathway.

To further investigate the role of the ILS pathway, we analyzed the role of DAF-16/FOXO transcription factor and found that the \( daf-16(mu86) \) loss-of-function mutation (Lin et al., 1997) fully abrogated the \( daf-2(e1370) \) protective effect on *E. coli* (Figure 6B). In contrast, \( daf-16(mu86) \) did not affect the efficiency of a *B. subtilis* mixed diet to inhibit aggregation (Figure 6B). Similarly, no increase in aggregation levels was observed in day 1 adults in *B. subtilis* PXN21 mutant worms fed with *B. subtilis* vegetative cells (Figure 6C). However, in day 3 adults worms fed on vegetative cells, loss of DAF-16 function led to a faster increase in the number of aggregates (Figure 6C), indicating that the later protection triggered by the vegetative cell diet relies partially on the activity of DAF-16. The hsf-1(ys441) mutation, which inhibits the second major transcription factor downstream of DAF-2, did not increase aggregation levels when grown on any *B. subtilis* diet (Figure 6D).

In conclusion, the effect of *B. subtilis* on \( \alpha \)-syn aggregation is independent of the ILS pathway in early adults. However, the protective effect later in adulthood induced by vegetative *B. subtilis* cells is mediated in part by the action of DAF-16. Thus, our results further indicate that *B. subtilis* spores and vegetative cells act redundantly through distinct protective mechanisms, with spores acting likely via PHA-4/DR and vegetative cells via DAF-16.

**\( B. \text{subtilis} \) Inhibits \( \alpha \)-Syn Aggregation by Altering Sphingolipid Metabolism in the Host**

To uncover the host response pathways that are modified by *B. subtilis* to induce the protective effect, we performed comparative global transcriptomics analysis (RNA sequencing [RNA-seq]) to compare young adult animals fed on two different diets: *E. coli* OP50 and *B. subtilis* PXN21 mixed state (Figure 7A). In addition, since the mixture of *E. coli* and *B. subtilis* retained much of the anti-aggregation effect but did not induce DR (see Figure 5E), we included this condition in the transcriptomics experiment to reveal DR-independent protective mechanisms.

We found that 6,510 genes were differentially expressed by 1.5-fold change or higher in animals fed with *B. subtilis* compared to those fed *E. coli* (false discovery rate [FDR] < 0.05, p value < 0.05) (Table S2). A summary of the top 50 most differentially expressed genes between *B. subtilis* and *E. coli*-fed animals, ranked by lowest FDR, is shown in Figure 7B. Sample clustering showed that the mix of both bacteria exhibited a gene expression profile closer to that of animals fed on *E. coli* than on *B. subtilis* (Figure S5A). In agreement with this, only 2,291 genes were found to be differentially expressed in this case (Figure 7C; Table S3). Of these, 343 genes were commonly upregulated and 359 downregulated in both animals fed with *B. subtilis* and the mixture of the two bacteria, compared to *E. coli* (Figure 7C; Tables S4 and S5). The RNaseq results were validated by randomly selecting 10 upregulated and downregulated genes and testing the level of expression by qRT-PCR (Figures S5B and S5C). As expected, pha-4 was significantly upregulated (1.35-fold change) only in animals fed on *B. subtilis*, compared with those fed on *E. coli* (Figure SSD), but showed no differences in animals fed on the mix of the two bacteria versus *E. coli*. No other DR-related transcription factors were differentially regulated at the transcript level in the different diets (Figure SSD).

Previous genome-wide screens on *C. elegans* models have identified modifiers of \( \alpha \)-syn aggregation (Hamamichi et al., 2008; Knight et al., 2014; van Ham et al., 2008). We intersected our transcriptomics datasets with these lists and found that a number of known suppressors of aggregation were upregulated by the *B. subtilis* diet (Table S6), indicating that *B. subtilis* may impart its effects on \( \alpha \)-syn through the activation of multiple protective pathways.

Next, we performed a Gene Ontology (GO) term analysis of gene sets affected by the two bacterial diets and found that 708 and 506 biological process (BP) terms were differentially regulated by *B. subtilis* and by the mix of the two bacteria, respectively (Table S7). The summaries of the 50 most significant non-redundant upregulated GO terms in *B. subtilis* and the mix versus *E. coli*, processed by REduce & Visualize Gene Ontology (REVIGO), are shown (Figures 7D and S5E). Among the top upregulated biological pathways by *B. subtilis* PXN21 are immune system processes, protein localization, redox processes, general metabolism, and, in particular, lipid metabolism. An expanded analysis of lipid-related terms revealed that several lipid-metabolism-related processes are significantly upregulated in both *B. subtilis* and the mixed diet, compared to *E. coli* (Figure 7E).
We focused on a specific pathway branch of lipid metabolism, the sphingolipid metabolism pathway, as it has been proposed to modify α-syn pathology in PD (Alecu and Bennett, 2019; Galvagnion, 2017; Lin et al., 2019; Plotegher et al., 2019). Ceramide lipid metabolism is the central hub of the sphingolipid metabolic pathway and was upregulated by both B. subtilis and mixed diets, with a p value <0.001 (Figures 7E and S5F). Genes in this pathway and was upregulated by both lipid metabolism is the central hub of the sphingolipid metabolic vagnion, 2017; Lin et al., 2019; Plotegher et al., 2019). Ceramide to modify the sphingolipid metabolism pathway, as it has been proposed (C) Average mixed-cell lawn (spore-rich). ****p < 0.0001, *p = 0.0358; n = 25 per time point per condition. Data shown are mean ± SEM from one representative experiment out of three with similar results, unless stated otherwise. ns, no significant differences.

DISCUSSION

The accumulation of misfolded α-syn into pathological aggregates plays a central role in the pathogenesis of PD and other synucleinopathies (Alafuzoff and Hartikainen, 2017). Significant effort has been invested into finding ways to suppress the formation or enhance the clearance of toxic α-syn aggregates as a treatment for PD (Savitt and Jankovic, 2019), though no such therapies are available yet. Previous studies suggest that the presence of distinct groups of bacteria in the gut microbiome modulate PD pathology (Minato et al., 2017; Sampson et al., 2016; Schepersjans et al., 2015). However, deciphering the precise effect of individual bacterial species remains challenging. In this study, we show that B. subtilis PXN21, a probiotic strain that is available for human consumption, both inhibits aggregation and efficiently removes preformed aggregates in a C. elegans model with ectopic expression of human α-syn.

It was previously reported that biofilm formation and NO production by B. subtilis confers C. elegans with stress resistance and enhanced longevity (Donato et al., 2017; Smolentseva et al., 2015). Our results reveal that while these pathways contribute to the suppression of α-syn later in life, the protective effect seen earlier in life is independent of these mechanisms. In young adults, the probiotic acts independently of gut colonization and triggers its protective effects partly via the production of bacterial metabolites other than NO.

We provide evidence that distinct metabolic states of the bacteria affect the physiology of the host as well as α-syn aggregation in different ways. B. subtilis spores, which are resistant to digestion and are metabolically inert, induce DR. DR conditions are known to activate the lysosomal autophagy pathway (Levine and Kroemer, 2008), one of the main systems of autophagy (Calvert et al., 2017). Our results reveal that while these pathways contribute to the suppression of α-syn later in life, the protective effect seen earlier in life is independent of these mechanisms. In young adults, the probiotic acts independently of gut colonization and triggers its protective effects partly via the production of bacterial metabolites other than NO.

We provide evidence that distinct metabolic states of the bacteria affect the physiology of the host as well as α-syn aggregation in different ways. B. subtilis spores, which are resistant to digestion and are metabolically inert, induce DR. DR conditions are known to activate the lysosomal autophagy pathway (Levine and Kroemer, 2008), one of the main systems of autophagy (Calvert et al., 2017). Our results reveal that while these pathways contribute to the suppression of α-syn later in life, the protective effect seen earlier in life is independent of these mechanisms. In young adults, the probiotic acts independently of gut colonization and triggers its protective effects partly via the production of bacterial metabolites other than NO.

We provide evidence that distinct metabolic states of the bacteria affect the physiology of the host as well as α-syn aggregation in different ways. B. subtilis spores, which are resistant to digestion and are metabolically inert, induce DR. DR conditions are known to activate the lysosomal autophagy pathway (Levine and Kroemer, 2008), one of the main systems of autophagy (Calvert et al., 2017). Our results reveal that while these pathways contribute to the suppression of α-syn later in life, the protective effect seen earlier in life is independent of these mechanisms. In young adults, the probiotic acts independently of gut colonization and triggers its protective effects partly via the production of bacterial metabolites other than NO.
Figure 7. *B. subtilis* Protects against α-Syn Aggregation by Changing the Sphingolipid Metabolism in the Host

(A) Assay strategy for the comparative transcriptomics experiment.

(B) Heatmap showing the top 50 most differentially expressed genes by false discovery rate (FDR) between *E. coli* and *B. subtilis* PXN21 or *E. coli* and *B. subtilis*: *E. coli* mix. A fold change \( \geq 1.5, p < 0.05, \) and FDR < 0.05 were considered for statistical significance.

(C) Venn diagrams showing the overlap between the statistically significant upregulated and downregulated genes in *B. subtilis* PXN21 versus the mix of *B. subtilis* and *E. coli* diet.

(D) Summary of the top 50 statistically significant non-redundant BP GO terms of *B. subtilis* PXN21 versus *E. coli* by log10 p value.

(E) Lipid-metabolism-related BP GO terms upregulated by *B. subtilis* PXN21 and the mix versus *E. coli* diets by log10 p value. Commonly upregulated lipid GO terms (top), *B. subtilis* exclusive (middle), and exclusive for the mix of *B. subtilis* and *E. coli* diet (bottom) are shown. Gray indicates processes not differentially regulated.

(F–J) Average α-syn aggregates of wild-type or mutant animals for sphingolipid metabolism genes: lagr-1(gk331) fed from the L1 with *B. subtilis* PXN21 mixed lawn diet (F) or vegetative cells (G); asm-3(ok1744) mutant animals fed from the L1 with *B. subtilis* PXN21 mixed lawn diet (H) or vegetative cells (I); sptl-3(ok1927) mutant animals fed from the L1 with *B. subtilis* PXN21 mixed lawn diet (J), compared to *E. coli*. \(* **p < 0.0001, \) **p < 0.01, *p < 0.01; ns, no significant differences. Mean values ± SEM, \( n = 50 \) worms per time point per condition from two independent experiments are shown.
C. elegans and is therefore a likely partial mechanism of action of B. subtilis spores. In contrast, B. subtilis vegetative cells protect via a DR-independent mechanism that partly depends on the action of DAF-16 in older animals. Downregulation of the ILS pathway, although implicated in the lifespan-extending effects of B. subtilis, is not required for the early protection against α-syn. Therefore, the anti-aggregation properties of B. subtilis remain, to a large extent, distinct from its anti-aging effects.

Our transcriptomics analysis revealed that part of the probiotic’s effect is mediated by alterations in the sphingolipid metabolism pathway, particularly the regulation of the enzymes LAGR-1/CERS1 (ceramide synthase), ASM-3/SMPD1 (acid sphingomyelinase), and SPTL-3/SPTLC2 (serine palmitoyltransferase). Previous studies suggest that an imbalance of lipids, including ceramides and sphingolipid intermediates, may contribute to the pathology of PD. For example, reduced levels of ceramides occur selectively in brain regions affected by PD pathology (Abbott et al., 2014). Several genetic risk loci in PD affect ceramide metabolism and cellular sphingolipid content (Ferrarra et al., 2016; Gan-Or et al., 2013; Henry et al., 2015; Lin et al., 2019; Plotegher et al., 2019), including mutations in ASM-3/SMPD1 (Foo et al., 2013; Gan-Or et al., 2015, 2013; Yönnen et al., 2017) and GBA (the lysosomal glucocerebrosidase). Furthermore, ASM-3/SMPD1 deficiency in cell-based models was shown to lead to α-syn accumulation (Alcalay et al., 2019), whereas inhibition of the Drosophila melanogaster ortholog of SPTL-3/SPTLC2 was found to suppress α-syn-associated neurodegenerative phenotypes (Lin et al., 2018). Furthermore, direct interactions between α-syn and lipids are known to modulate the aggregation propensity of this protein both in vitro and in vivo (Galvagnion, 2017). We propose that the B. subtilis probiotic diet in the C. elegans model alters the lipid composition of the cell, directly affecting α-syn aggregation. Our data further demonstrate that a simple dietary intervention can concurrently affect several branches of the sphingolipid pathway, to beneficial effect.

PD is typified by the presence of intraneuronal α-syn aggregation and dopaminergic degeneration (Poewe et al., 2017). Our current study is based on an established C. elegans model that expresses human α-syn in muscle cells, which allows us to assess aggregation in vivo. The effects of B. subtilis on the nervous system, as well as its efficacy in mouse models of PD, present promising avenues of future investigation. The prospect of B. subtilis modifying α-syn aggregation in humans could open exciting possibilities for diet-based, disease-modifying interventions through the manipulation of microbiome composition in the gastrointestinal tract or the development of drug therapies based on protective bacterial metabolites.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Nematode and bacterial strains
- **METHOD DETAILS**
  - C. elegans growth conditions
  - Bacterial growth conditions
  - Characterization of biofilm formation by B. subtilis strains
  - Experiments with killed bacteria
  - Experiments with bacterial extracts
  - Nitric Oxide (NO) experiments
  - Quantification of aggregation
  - Locomotion analysis
  - Lifespan assays
  - Quantification of life-traits
  - Immunoblot analysis
  - Nematode RNA Sequencing
  - Reverse transcription and quantitative real-time PCR (qRT-PCR)
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND CODE AVAILABILITY**

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/. ceirep.2019.12.078.

ACKNOWLEDGMENTS

We thank Claire Bénard, Sebastian Greiss, Oliver Hobert, Anton Gartner, Luisa Cochella, Emanuel Busch, Diego Golombek, Ailish Tynan and Claudio Valverde for helpful discussions and feedback on the manuscript; EdinOmics and Tessa Moses for expert assistance; Viktoria Bajuszova for technical support; Francis Turner and Edinburgh Genomics for RNA-seq analysis; José C. Riquelme, Crispin Jordan, and Ignacio Spiousas for input on statistical analysis; Elen Nollen for the NLS901 strain; Life Science Editors for editing assistance; and Ms. Vickie Cumnane for her generous donation. Funding sources include EMBO ALTF 529-2017 and MSCA-IF 798650 to M.E.G.; Parkinson’s UK, United Kingdom, project grant PRO-17-21 to M.D. and F.X.; BB/SRC, United Kingdom, BB/P001335/1 grant to N.R.S.-W. and BB/R50614X/1 grant to K.L.B. which supports J.B.; and the Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund ISSF3 award to M.D. Some strains were provided by the CGC, funded by NIH Office of Research Infrastructure Programs (P40 OD010440), the Baseball Genetic Stock Centre funded by the National Science Foundation (1756219), and the Gene Knockout Project at the Oklahoma Medical Research Foundation. The Wormlab was acquired with funding from the Mair Maxell Epilepsy Centre.

AUTHOR CONTRIBUTIONS

M.D., M.E.G., F.X., C.S.-T.-Q., and L.R.-D. designed, performed, and analyzed experiments with C. elegans; J.B. and K.L.B. designed, performed, and analyzed western blot experiments; N.R.S.-W. and S.A. designed, performed, and analyzed B. subtilis biofilm experiments and generated bacterial strains; A.R. contributed with the RNA-seq and qRT-PCR analysis; and M.D. provided oversight for the project and wrote the paper. All authors contributed to editing the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: July 15, 2019
Revised: October 23, 2019
Accepted: December 19, 2019
Published: January 14, 2020
REFERENCES

Abbott, S.K., Li, H., Muñoz, S.S., Knoch, B., Batterham, M., Murphy, K.E., Halliday, G.M., and Garner, B. (2014). Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease. Mov. Disord. 29, 518–526.

Alafuzoff, I., and Hartikainen, P. (2017). Alpha-synucleinopathies. Handb. Clin. Neurol. 145, 339–353.

Alcalý, R.N., Mallett, V., Vanderperre, B., Tavassoly, O., Dauvilliers, Y., Wu, R.Y.J., Ruskey, J.A., Leblond, C.S., Ambalavanan, A., Laurent, S.B., et al. (2019). SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson’s disease. Mov. Disord. 34, 526–535.

Alecu, I., and Bennett, S.A.L. (2019). Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease. Front. Neurosci.

Boertien, J.M., Pereira, P.A.B., Aho, V.E.T., and Scheperjans, F. (2019). Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease: A Systematic Review. J. Parkinsons Dis. 9, S927–S932.

Braak, H., Rub, U., Gai, W.P., and Del Tredici, K. (2003). Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. (Vienna) 110, 517–536.

Branda, S.S., González-Pastor, J.E., Ben-Yehuda, S., Losick, R., and Kolter, R. (2001). Fruiting body formation by Bacillus subtilis. Proc. Natl. Acad. Sci. USA 98, 11621–11626.

Branda, S.S., Vik, S., Friedman, L., and Kolter, R. (2005). Biofilms: the matrix revisited. Trends Microbiol. 13, 20–26.

Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 71–94.

Budovskaya, Y.V., Wu, K., Southworth, L.K., Jiang, M., Tesco, P., Johnson, T.E., and Kim, S.K. (2014). An elt-3/elt-5/elt-6 GATA transcription circuit guides nematode longevity through downregulation of the insulin-like signalling pathway. Nat. Commun. 5, 14332.

Fahn, S. (2015). The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov. Disord. 30, 4–18.

Ferrazza, R., Cogo, S., Melrose, H., Bubacco, L., Greggio, E., Guella, G., Ciciero, L., and Ploetheger, N. (2016). LRRK2 deficiency impacts ceramide metabolism in brain. Biochem. Biophys. Res. Commun. 478, 1141–1146.

Fon, J.N., Lianny, H., Sinfelt, A., Yu, X.Q., Liu, J., Moore, W.L., Prakash, K.M., Tan, L.C., and Tan, E.K. (2013). Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson’s disease. Neurobiol Aging 34, 2890.e13-5.

Fung, T.C., Olson, C.A., and Hsiao, E.Y. (2017). Interactions between the microbiota, immune and nervous systems in health and disease. Nat. Neurosci. 20, 145–155.

Galvagnion, C. (2017). The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson’s Disease. J. Parkinsons Dis. 7, 433–450.

Gan-Or, Z., Ozelius, L.J., Bar-Shira, A., Saunders-Pullman, R., Mirelman, A., Komreich, R., Gana-Weisz, M., Raymond, D., Rozenkrantz, L., Deik, A., et al. (2013). The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 80, 1606–1610.

Grau, R. (2017). Bacillus subtilis biofilm extends Caenorhabditis elegans longevity. EMBO J.

Greer, E.L., Dowlatshahi, D., Banko, M.R., Villen, J., Hoang, K., Blanchard, D., Gygi, S.P., and Brunet, A. (2007). An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr. Biol. 17, 1646–1656.

Greshoff, K.J., Rothman, S.M., Ladenheim, B., Wan, R., Vranis, N., Hutchison, E., Okun, E., Cadet, J.L., and Mattson, M.P. (2013). Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant α-synuclein. Neurobiol. Aging 34, 928–935.

Guedes, A., Ludovico, P., and Sampaio-Marques, B. (2017). Caloric restriction alleviates alpha-synuclein toxicity in aged yeast cells by controlling the opposite roles of Tor1 and Sir2 on autophagy. Mech. Ageing Dev. 161, 270–276.

Gusarov, I., Gutiérrez, L., and Plotegher, N. (2016). LRRK2 deficiency impacts ceramide metabolism in brain. Biochem. Biophys. Res. Commun.

Henry, A.G., Aghamohammadzadeh, S., Samaroo, H., Chen, Y., Mou, K., Needle, E., and Hirst, W.D. (2015). Pathogenic LRRK2 mutations, through
increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum. Mol. Genet. 24, 6013–6028.

Hobley, L., Ostrowski, A., Rao, F.V., Bromley, K.M., Porter, M., Prescott, A.R., MacPhee, C.E., van Aalten, D.M., and Stanley-Wall, N.R. (2013). BsiA is a self-assembling bacterial hydrophobin that coats the Bacillus subtilis subtilis biofilm. Proc. Natl. Acad. Sci. USA 110, 13600–13605.

Howe, E., Holton, K., Nair, S., Schlauch, D., Sinha, R., and Quackenbush, J. (2010). MeV: MultiExperiment Viewer. In Biomedical Informatics for Cancer Research (Springer), pp. 267–277.

Hsu, A.L., Murphy, C.T., and Kenyon, C. (2003). Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300, 1142–1145.

Jiang, J.C., Krchin, P.A., Zaguishi, M., Hunt, J., and Jazwinski, S.M. (1998). Homologs of the yeast longevity gene LAG1 in Caenorhabditis elegans and humans. Genome Res. 8, 1259–1272.

Kaminski Schierle, G.S., Bertocconi, C.W., Chan, F.T.S., van der Goot, A.T., Schwedler, S., Skepper, J., Schlachter, s., van Ham, T., Esposito, A., Kumita, J.R., et al. (2011). A FRET sensor for non-invasive imaging of amyloid formation in vivo. ChemPhysChem 12, 673–680.

Kaufu, B.B., Carrasquilla, A., Hicks, M.L., Caldwell, K.A., and Caldwell, G.A. (2013). Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling. Neurosci. Lett. 541, 116–119.

Kenyon, C., Chang, J., Gems, E., Rudner, A., and Tabtiang, R. (1993). A C. elegans mutant that lives twice as long as wild type. Nature 366, 461–464.

Kim, Y., and Sun, H. (2012). ASM-3 acid sphingomyelinase functions as a positive regulator of the DAF-2/AGE-1 signaling pathway and serves as a novel anti-aging target. PLoS ONE 7, e45890.

Kimura, K.D., Tissenbaum, H.A., Liu, Y., and Ruvkun, G. (1997). daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277, 942–946.

Knight, A.L., Yan, X., Hamamichi, S., Ajuri, R.R., Mazzulli, J.R., Zhang, M.W., Daigle, J.G., Zhang, S., Borom, A.R., Roberts, L.R., et al. (2014). The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson’s models. Cell Metab. 20, 145–157.

Kobayashi, K., and Iwano, M. (2012). BslA(YuaB) forms a hydrophobic layer on the surface of Bacillus subtilis biofilms. Mol. Microbiol.

Kolde, R. (2015). heatmap: Pretty Heatmaps. R package version 1.0-8. https://CRAN.R-project.org/package=heatmap.

Koo, B.M., Kritikos, G., Farell, J.D., Todor, H., Kong, K., Kinsey, H., Wapinski, I., Galaridini, M., Cabal, A., Peters, J.M., et al. (2017). Construction and Analysis of Two Genome-Scale Deletion Libraries for Bacillus subtilis. Cell Syst. 4, 291–305.e297.

Kuwahara, T., Koyama, A., Koyama, S., Yoshina, S., Ren, C.H., Kato, T., Mitani, S., and Ivatsubo, T. (2008). A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum. Mol. Genet. 17, 2997–3009.

Laaberki, M.H., and Dworkin, J. (2008). Role of spore coat proteins in the resistance of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Science 327, 1319–1322.

Lin, G., Lee, P.T., Chen, K., Mao, D., Tan, K.L., Zuo, Z., Lin, W.W., Wang, L., and Bellen, H.J. (2018). Phospholipase PL2AG6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to alpha-Synuclein Gain. Cell Metab. 28, 605–618.e606.

Lin, G., Wang, L., Marcogliese, P.C., and Bellen, H.J. (2019). Sphingolipids in the Pathogenesis of Parkinson’s Disease and Parkinsonism. Trends Endocrinol. Metab. 30, 106–117.

Lloyd-Pierce, J., Abu-Alli, G., and Huttenhower, C. (2016). The healthy human microbiome. Genome Med. 8, 51.

Luo, W., and Brouwer, C. (2013). Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics 29, 1830–1831.

Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal 17, 10–12.

McKay, J.P., Raizen, D.M., Gottschalk, A., Schafer, W.R., and Avery, L. (2004). eat-2 and eat-18 are required for nicotinic neurotransmission in the Caenorhabditis elegans pharynx. Genetics 166, 161–169.

Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Ohno, K., and Hirayama, M. (2017). Progression of Parkinson’s disease is associated with gut dysbiosis: Two-year follow-up study. PLoS ONE 12, e0187307.

Myake, Y., Kozutsumi, Y., Nakamura, S., Fujita, T., and Kawasaki, T. (1995). Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem. Biophys. Res. Commun. 217, 396–403.

Mok, D.Z., Sternberg, P.W., and Inoue, T. (2015). Morphologically defined sub-stages of C. elegans vulval development in the fourth larval stage. BMC Dev. Biol. 15, 26.

Morley, J.F., Brignull, H.R., Weyers, J.J., and Morimoto, R.I. (2002). The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 99, 10417–10422.

Nicholson, W.L., and Setlow, P. (1990). Sporulation, germination, and outgrowth. In Molecular Biological Methods for Bacillus (John Wiley and Sons), pp. 391–450.

Ogg, S., Paradis, S., Gottlieb, S., Patterson, G.J., Lee, L., Tissenbaum, H.A., and Ruvkun, G. (1997). The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389, 994–999.

Ostrowski, A., Mehert, A., Prescott, A., Kiley, T.B., and Stanley-Wall, N.R. (2011). YuaB functions synergistically with the exopolysaccharide and TasA amyloid fibers to allow biofilm formation by Bacillus subtilis. J. Bacteriol. 193, 4821–4831.

Panowski, S.H., Wolff, S., Agullianu, H., Durieux, J., and Dillin, A. (2007). PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature 447, 550–555.

Ploteğer, N., Babucko, L., Greggio, E., and Civiero, L. (2019). Ceramides in the Pathogenesis of Parkinson’s Disease: From Recent Evidence to New Hypotheses. Front. Neurosci. 13, 330.

Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkman, J., Schrag, A.E., and Lang, A.E. (2017). Parkinson disease. Nat. Rev. Dis. Primers 3, 17013.

Pringsheim, T., Jette, N., Frolikis, A., and Steeves, T.D. (2014). The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov. Disord. 29, 1583–1590.
Pujol, J., Peña-Díaz, S., Lázaro, D.F., Pecciati, F., Pinheiro, F., González, D., Carjia, A., Navarro, S., Conde-Giménez, M., García, J., et al. (2018). Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc. Natl. Acad. Sci. USA 115, 10481–10486.

Qiao, L., Hamamichi, S., Caldwell, K.A., Caldwell, G.A., Yacobian, T.A., Wilson, S., Xie, Z.L., Speake, L.D., Parks, R., Crabtree, D., et al. (2008). Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain 1, 17.

Rietdijk, C.D., Perez-Pardo, P., Garssen, J., van Wezel, R.J., and Kraneveld, A.D. (2017). Exploring Braak’s Hypothesis of Parkinson’s Disease. Front. Neurol. 8, 37.

Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47.

Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140.

Romero, D., Aguilar, C., Losick, R., and Kotler, R. (2010). Amyloid fibers provide structural integrity to Bacillus subtilis biofilms. Proc. Natl. Acad. Sci. USA 107, 2230–2234.

Roodveldt, C., Bertonacci, C.W., Andersen, A., van der Goot, A.T., Hsu, S.T., Fernández-Montesinos, R., de Jong, J., van Ham, T.J., Nollen, E.A., Pozo, D., et al. (2009). Chaperone proteostasis in Parkinson’s disease: stabilization of the Hsp70/alpha-synuclein complex by Hip. EMBO J. 28, 3738–3770.

Ross, C.A., and Poirier, M.A. (2004). Protein aggregation and neurodegeneration. Cell 116, 235–245.

Ruan, Q., Harrington, A.J., Caldwell, K.A., Caldwell, G.A., and Standaert, D.G. (2010). VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson’s disease. Neurobiol. Dis. 37, 330–338.

Rampersad, T., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Joubert, V., et al. (2016). Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. Disord. 31, 1749–1762.

Untergasser, A., Nijven, H., Rao, X., Bisseling, T., Geurts, R., and Leunissen, J.A. (2007). Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 35, W71–4.

van Gestel, J., Weissing, F.J., Kuipers, O.P., and Kovács, Á.T. (2014). Density of founder cells affects spatial pattern formation and cooperation in Bacillus subtilis biofilms. ISME J. 8, 2069–2079.

van Ham, T.J., Thijsen, K.L., Breitling, R., Hofstra, R.M., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550.

Watson, E., MacNeil, L.T., Ritter, A.D., Yilmaz, L.S., Rosebrock, A.P., Caudy, A.A., and Walthou, A.J.M. (2014). Interspecies Systems Biology Uncovers Metabolites Affecting C. elegans Gene Expression and Life History Characteristics. Cell 156, 1336–1337.

Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, M., Loher, T., Vilar, M., Campioni, S., et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 4194–4199.

Wu, D., Lim, E., Vaillant, F., Asselin-Labat, M.L., Visvader, J.E., and Smyth, G.K. (2010). ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics 26, 2176–2182.

Ylönen, S., Siitonen, A., Nails, M.A., Ylikotila, P., Autere, J., Hiltunen, M., Tienari, P.J., Soininen, H., et al. (2017). Genetic risk factors in Finnish patients with Parkinson’s disease. Parkinsonism Relat. Disord. 45, 39–43.

York, K., Kenney, T.J., Satola, S., Moran, C.P., Jr., Poth, H., and Youngman, P. (1992). SpOpA controls the sigma A-dependent activation of Bacillus subtilis sporulation-specific transcription unit spo0E. J. Bacteriol. 174, 2648–2658.

Zhang, S., Glukhova, S.A., Caldwell, K.A., and Caldwell, G.A. (2017). NCEH-1 modulates cholesterol metabolism and protects against α-synuclein toxicity in C. elegans model of Parkinson’s disease. Hum. Mol. Genet. 26, 3823–3836.
# STAR★METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Mouse monoclonal antibody anti-α-synuclein | BD Biosciences | Cat# 610786; RRID: AB_398107 |
| Mouse monoclonal anti-β-actin | Sigma-Aldrich | Cat# A5441; RRID: AB_476744 |
| Mouse monoclonal anti-β-Tubulin | Sigma-Aldrich | Cat# T4026; RRID: AB_477577 |
| Rabbit Polyclonal Anti-Mouse | Agilent | Cat# P0260; RRID: AB_2636929 |
| **Bacterial and Virus Strains** |        |            |
| E. coli: OP50 | CGC | RRID:WB-STRAIN:OP50 |
| B. subtilis: probiotic PXN21 | Bio-Kult by ADM-Protexin | N/A |
| B. subtilis: NCIB 3610 Marburg, undomesticated | BGSC | BGSCID: 3A1 |
| B. subtilis: NRS2097 NCIB 3610 ΔbslA::cmlR | Nicola Stanley-Wall (Ostrowski et al., 2011) | N/A |
| B. subtilis: NRS2415 NCIB 3610 ΔtasA::spcR | Nicola Stanley-Wall (Ostrowski et al., 2011) | N/A |
| B. subtilis: NRS2450 NCIB 3610 Δeps(A-O)::tetR | Nicola Stanley-Wall (Ostrowski et al., 2011) | N/A |
| B. subtilis: NRS2543 NCIB 3610 Δeps(A-O)::tetR ΔtasA::spcR ΔbslA::cmlR | Nicola Stanley-Wall (Ostrowski et al., 2011) | N/A |
| B. subtilis: NCIB 3610 amyE Phyper-spank-mKate2::spcR | Akos T. Kovacs (van Gestel et al., 2014) | N/A |
| B. subtilis: NRS8582 NCIB 3610 amyE::Phyper-spank-mKate2::spcR | Nicola Stanley-Wall | N/A |
| B. subtilis: NRS6296 NCIB 3610 ΔnosA::kanR | Nicola Stanley-Wall | N/A |
| B. subtilis: NRS6297 NCIB 3610, ΔphrC::kanR | Nicola Stanley-Wall | N/A |
| B. subtilis:168 trpC2; ΔspoIIE::kanR | Addgene-BGSC (Koo et al., 2017) | Cat# 1000000115 |
| B. subtilis:168 trpC2; ΔnosA::kanR | Addgene-BGSC (Koo et al., 2017) | BGSCID: BKK00640 |
| B. subtilis:JH642 | BGSC | BGSCID: 1A96 |
| Bacteriophage: Bacillus phage SPP1 | Anne Moir (University of Sheffield) | N/A |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| Agar | Formedium | Cat# AGA02 |
| Select Agar | Thermo Fisher Scientific | Cat#30391023 |
| Bacto peptone | BD Biosciences | Cat# 211677 |
| Sodium Hypochlorite solution (4.00-4.99%) | Honeywell | Cat# 239305 |
| Ca(NO3)2 | Sigma-Aldrich | Cat# C196 |
| CaCl2 | Sigma-Aldrich | Cat# 449709 |
| Coomassie Brilliant Blue G-250 | Thermo Fisher Scientific | Cat# 20279 |
| Schaeffer and Fulton Spore Stain Solution A | Sigma-Aldrich | Cat# 90903 |
| Schaeffer and Fulton Spore Stain Solution B | Sigma-Aldrich | Cat# 39955 |
| Dichloromethane (DCM) | Thermo Fisher Scientific | Cat# 420152 |
| Nutrient broth No 3 | Sigma-Aldrich | Cat# 70149 |
| Dried Milk Powder | Marvel | N/A |
| Dithiothreitol (DTT) | GE Healthcare | Cat# 17-1318-01 |
| Ethanol | ACROS Organics | Cat# AC615095000 |
| Ethyl acetate | Sigma-Aldrich | Cat# 319902 |
| EDTA | Sigma-Aldrich | Cat# 798681 |
| FeCl3 | Sigma-Aldrich | Cat# 451649 |
| FeSO4 | Sigma-Aldrich | Cat# 450278 |
| L-glutamic acid monosodium salt monohydrate | Sigma-Aldrich | Cat# 49621 |

(Continued on next page)
### REAGENTS or RESOURCES SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Glycerol ≥ 99.5%    | Thermo Fisher Scientific | Cat# BP229-1 |
| HEPES sodium salt   | Sigma-Aldrich | Cat# H7006 |
| Hydrogen peroxide solution | Sigma-Aldrich | Cat# 216763 |
| Kanamycin Sulfate   | Coming | Cat# 61-176-RG |
| KCl                 | Sigma-Aldrich | Cat# P9541 |
| KH2PO4              | ACROS Organics | Cat# AC424200025 |
| K2HPO4              | ACROS Organics | Cat# AC424190025 |
| L-Arginine          | Alfa Aesar | Cat# A15738 |
| Levamisole Hydrochloride | MP Biomedicals | Cat# 155228 |
| Luminal 97%         | Sigma-Aldrich | Cat# 123072 |
| Luria-Bertani (LB) broth | Sigma-Aldrich | Cat# L3022 |
| Lysozyme            | Thermo Fisher Scientific | Cat# 89833 |
| MgCl2               | Sigma-Aldrich | Cat# M8266 |
| MnCl2               | Sigma-Aldrich | Cat# 244589 |
| MOPS                | Sigma-Aldrich | Cat# M1254 |
| Na2HPO4             | ACROS Organics | Cat#AC204851000 |
| NaCl                | Thermo Fisher Scientific | Cat# BP358-1 |
| NaF                 | Sigma-Aldrich | Cat# S7920 |
| NaOH                | Thermo Fisher Scientific | Cat# S612-3 |
| NativePAGE 4-16% Bis-Tris-gels | Thermo Fisher Scientific | Cat# BN1002BOX |
| NativePAGE 20x Running buffer | Thermo Fisher Scientific | Cat# BN2001 |
| Nitrocellulose membrane 0.2 μm | Biorad | Cat# 1620112 |
| MAHMA NONOate (NO donor) | Sigma-Aldrich | Cat# M1555 |
| NuPAGE 4-12% Bis-Tris-gels | Invitrogen | Cat# NP0322PK2 |
| PageRuler Protein Ladder, 10 to 250 kDa | Thermo Fisher Scientific | Cat# 26620 |
| PBS                 | Sigma-Aldrich | Cat# P4417 |
| P-Coumaric acid     | Sigma-Aldrich | Cat# C9108 |
| Penicillin Streptomycin | GIBCO | Cat# 15070063 |
| PFA                 | Sigma-Aldrich | Cat# |
| Procase Inhibitor Mix | GE Healthcare | Cat# 80-6501-23 |
| Proteinase K        | BioVision | Cat# 9211-5 |
| Thiamine hydrochloride | Sigma-Aldrich | Cat# T4625 |
| Triton X-100        | MP Biomedicals | Cat# 807423 |
| TWEEN® 20           | Sigma-Aldrich | Cat# P1379 |
| ZnCl2               | Sigma-Aldrich | Cat# 229997 |

### Critical Commercial Assays

- **OneTaq® 2X Master Mix with Standard Buffer** (New England Biolabs (NEB)) | Cat# M0482S
- **GoTaq® G2 Green Master Mix** (Promega) | Cat# M782A
- **QIAquick PCR Purification Kit** (QIAGEN) | Cat# 28104
- **Qubit RNA BR kit** (Thermo Fisher Scientific) | Cat# Q10210
- **Quick Start Bradford Protein Assay Kit** (Bio-Rad) | Cat# 5000201
- **Quick-RNA Microprep Kit** (ZYMOS Research) | Cat# R1050
- **Q5 High-Fidelity 2X Master Mix** (NEB) | Cat# M0492S
- **SuperScript IV First-Strand Synthesis System** (Thermo Fisher Scientific) | Cat# 18091050
- **TruSeq Stranded mRNA kit** (Illumina) | Cat# 20020594
- **LightCycler® 480 SYBR Green I master** (Roche) | Cat# 04707516001
- **Zymoclean Gel DNA Recovery Kit** (ZYMOS Research) | Cat# D4001

### Deposited Data

- **C. elegans RNA-Seq reads (fastq files)** | This study | ArrayExpress: E-MTAB-8164

(Continued on next page)
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Maria Doitsidou (maria.doitsidou@ed.ac.uk).

**EXPANSION**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Experimental Models: Organisms/Strains** |
| C. elegans: N2 Bristol | CGC | CGCRRID:WB-STRAIN:N2 |
| C. elegans: NL5901 pkls2386[Punc-54::x-synuclein::YFP + unc-119(+)] | Ellen Nollen (van Ham et al., 2008) | RRID:WB-STRAIN:NL5901 |
| C. elegans: MDH586 daf-2(e1370) III; pkls2386 | This study | N/A |
| C. elegans: MDH585 daf-16(mu86) I; pkls2386 | This study | N/A |
| C. elegans: MDH587 hsf-1(sy441) I; pkls2386 | This study | N/A |
| C. elegans: MDH657 daf-2(e1370) III; daf-16(mu86) I; pkls2386 | This study | N/A |
| C. elegans: MDH611 eat-2(ad465) II; pkls2386 | This study | N/A |
| C. elegans: MDH711 lagr-1(pk331) I, pkls2386 | This study | N/A |
| C. elegans: MDH724 asm-3(ok1744) IV; pkls2386 | This study | N/A |
| C. elegans: MDH725 splt-3(ok1927) II; pkls2386 | This study | N/A |
| **Oligonucleotides** |
| For information regarding oligonucleotide sequences used in this study please refer to Table S9 | This study | Table S9 |

**Software and Algorithms**

| Tool | Version | Source |
|------|---------|--------|
| Cutadapt | cutadapt-1.9.dev2 | Martin, 2011 [https://cutadapt.readthedocs.io/en/stable/](https://cutadapt.readthedocs.io/en/stable/) |
| EdgeR | 3.16.5 | Lun et al., 2016; Robinson et al., 2010 [https://bioconductor.org/packages/release/bioc/html/edgeR.html](https://bioconductor.org/packages/release/bioc/html/edgeR.html) |
| FeatureCounts | 1.5.3 | Liao et al., 2014 [http://subread.sourceforge.net](http://subread.sourceforge.net) |
| Fiji | Schindelin et al., 2012 | [http://fiji.sc/](http://fiji.sc/) |
| GraphPad Prism | | GraphPad Software, La Jolla California USA [https://www.graphpad.com](https://www.graphpad.com) |
| ImageJ | | Schneider et al., 2012 [https://imagej.nih.gov/ij/](https://imagej.nih.gov/ij/) |
| Limma | 3.30.13 | Ritchie et al., 2015 [https://bioconductor.org/packages/release/bioc/html/limma.html](https://bioconductor.org/packages/release/bioc/html/limma.html) |
| Multiple Experiment Viewer | 4.9.0_r2731 | Howe et al., 2010 [http://mev.tm4.org/](http://mev.tm4.org/) |
| OASIS 2 | Han et al., 2016; Oncotarget 11269 | [https://sbi.postech.ac.kr/oasis2/](https://sbi.postech.ac.kr/oasis2/) |
| Pathview | 1.24.0 | [https://bioconductor.org/packages/release/bioc/html/pathview.html](https://bioconductor.org/packages/release/bioc/html/pathview.html) |
| Pheatmap | | [https://github.com/cran/pheatmap/](https://github.com/cran/pheatmap/) |
| Photoshop | | Adobe Systems Inc. [https://www.adobe.com/Photoshop](https://www.adobe.com/Photoshop) |
| Primer3Plus | | Untergasser et al., 2007 [http://bioinfo.ut.ee/primer3/](http://bioinfo.ut.ee/primer3/) |
| R-3.5.1 | R Core Team | [https://www.r-project.org/](https://www.r-project.org/) |
| SnapGene | | SnapGene software from GSL Biotech [https://www.snapgene.com/](https://www.snapgene.com/) |
| STAR | 2.5.2b | Dobin et al., 2013 [http://code.google.com/p/ma-star/](http://code.google.com/p/ma-star/) |
| Illustrator | | Adobe Systems Inc. [https://www.adobe.com/products/illustrator](https://www.adobe.com/products/illustrator) |
| WormLab tracking platform | | MBF Bioscience, Williston, VT USA [https://www.mbfbioscience.com/wormlab](https://www.mbfbioscience.com/wormlab) |

**LEAD CONTACT AND MATERIALS AVAILABILITY**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Maria Doitsidou (maria.doitsidou@ed.ac.uk).

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Nematode and bacterial strains**

All bacterial and nematode strains used and generated in this study can be found in the Key Resources Table.
Several bacterial strains were used in this study. *E. coli* OP50 was obtained from the CGC. The *B. subtilis* PXN21 strain (Colenutt and Cutting, 2014) was isolated from Bio-Kult Advanced Multi-Strain Formulation dietary supplement (https://www.bio-kult.com, ADM-Protexin) and genotyped using universal 16S rRNA primers (Lane, 1991) (See Table S9 for primers). The wild-type undomesticated *B. subtilis* NCIB 3610 and the laboratory 168 and JH64102 strains were obtained from the Bacillus Genetic Stock Center (BGSC) (http://www.bsgc.org). 168-based deletion strain *jspollE* was obtained from Addgene (www.addgene.org) as part of the *B. subtilis* Single Gene Deletion Library with Kanamycin resistance (Koo et al., 2017). The NCIB 3610 deficient derivatives strains ΔtasA::cml, ΔbslA::spc, Δeps(A-O)::tet, Δnos::kan and ΔphrC::kan and the triple ΔbslA::spc; eps(A-O)::tet; tasA::cml, were obtained from the Nicola Stanley-Wall lab. SPP1 phage transductions were used to introduce DNA into *B. subtilis* NCIB 3610 strains from 168 derivatives (Verhamme et al., 2007). Drug resistance cassettes are indicated as follows: cml, chloramphenicol resistance; kan, kanamycin resistance; erm, erythromycin resistance; tet, tetracycline resistance and spc, spectinomycin resistance.

### METHOD DETAILS

**C. elegans** growth conditions

Nematodes were handled according to standard practices (Brenner, 1974; Stiernagle, 2006). Worm strains were grown on NGM plates for experiments with mixed spores and vegetative cells, NGM plus 0.5 mM of arginine for experiments with vegetative cells (to avoid sporulation), or NGM without peptone for experiments with spores only (to avoid germination). All strains were grown at 20°C unless otherwise indicated. Worms were synchronized by the alkaline hypochlorite method (Stiernagle, 2006) and left nutating every two days. For the food switch experiments, worms were grown on OP50 until L4 stage, then shifted to a new diet and transferred to new plates every two days thereafter. To set up a biofilm, worms were grown on *E. coli* OP50 until L4 stage, then shifted to a new diet and transferred to new plates every two days thereafter.

**Bacterial growth conditions**

Bacterial cultures were grown until an OD<sub>600</sub> of 1 in Luria-Bertani (LB) media at 37°C with agitation (220 rpm). 330 μL of a 2x concentrated culture was seeded on 55 mm unvented NGM plates. Seeded plates were left to dry and grow for 3 days at room temperature for experiments with mixed spores and vegetative cells, or overnight for experiments with vegetative cells only. To obtain spore-pure bacterial cultures, PXN21 *B. subtilis* bacteria were grown in Schaeffer’s sporulation medium (SSM) as previously described (Donato et al., 2017) (containing per liter: 8 g of Difco Bacto-nutrient broth, 10 mL of 10% w/v KCl, 10 mL of 1.2% w/v MgSO<sub>4</sub>·7H<sub>2</sub>O, ~1.50 mL of 1 M NaOH up to pH 7.6, 1.0 mL of 1 M Ca(NO<sub>3</sub>)<sub>2</sub>, 1.0 mL of 0.010 M MnCl<sub>2</sub>, and 1.0 mL of 1 mM FeSO<sub>4</sub>). Briefly, bacteria were grown in SSM medium at 37°C for 48 h. The culture was heat-treated for 20 min at 80°C to kill vegetative cells and then spun down. To obtain pure spores, the heat-treated pelleted cells was treated three times with lysozyme (25 μg/mL; for 30 min at 37°C), washed each time with cold deionised water and centrifuged until the culture consisted of only phase-bright spores. The efficiency of the purification was tested by the Schaeffer Fulton staining method.

**Characterization of biofilm formation by *B. subtilis* strains**

*B. subtilis* biofilms were grown on MSgg medium (5 mM potassium phosphate and 100 mM MOPS at pH 7.0 supplemented with 2 mM MgCl<sub>2</sub>, 700 μM CaCl<sub>2</sub>, 50 μM MnCl<sub>2</sub>, 50 μM FeCl<sub>3</sub>, 1 μM ZnCl<sub>2</sub>, 2 μM thiamine, 0.5% glycerol, 0.5% glutamate) (Brandt et al., 2001) solidified with 1.5% select agar (Invitrogen) at 30°C at the indicated time points. To set up a biofilm, a 3 mL aliquot of LB medium was inoculated with an individual colony taken from an overnight plate and grown at 37°C to an OD<sub>600</sub> of 1. Then 5 μL of the culture was placed onto an MSgg plate which was incubated at 30°C for morphology and hydrophobicity studies. Images of colony biofilms were recorded using a Leica MZ16FA stereomicroscope. Biofilm hydrophobicity was determined by placing a 5 μL droplet of water on the upper surface of biofilms that had been grown for 48 hours at 30°C (Hobley et al., 2013). The water droplet was allowed to equilibrate for 5 minutes prior to imaging using a ThetaLite TL100 optical tensiometer (Biolin Scientific).
Experiments with killed bacteria
For dietary restriction (DR) with killed E. coli OP50 experiments, bacterial cultures were grown as previously described until an OD$_{600}$ of 1. DR was induced by seeding 200 µL of a 1x concentrated culture on 55 mm unvented NGM plate and the same amount but twice concentrated (2x final) was used for normal growth conditions. E. coli culture was completely spread in the plates and left to dry and grow for 24 h or 48 h. Bacteria were killed by UV irradiation (Watson et al., 2014) (254 nm, 5 J/cm$^2$), using a UV crosslinker (CL 508, Cleaver Scientific).

For the experiments with killed B. subtilis PXN21, bacterial cultures were grown as previously described until an OD$_{600}$ of 1 to have only vegetative cells present. 200 µL of a 2x concentrated culture were completely spread on 55 cm unvented NGM + 0.5 mM arginine plate and left to dry and grow for only 24h. Bacteria were killed by a combination of UV irradiation (254 nm, 5 J/cm$^2$) and antibiotics treatment (200 µg/mL kanamycin and 1mg/mL carbenicillin) for 3h before transferring the worms onto them (Smolentseva et al., 2017). In all the conditions, the efficiency of the killing protocol was tested by sampling and streaking the killed bacteria in LB agar plates and incubated overnight at 37°C.

Experiments with bacterial extracts
B. subtilis PXN21 was inoculated from a fresh colony into 1 L of LB and left to grow at 37°C and 220 rpm for 48 h. Under this condition, the cultures of this strain are very saturated and reach a final OD$_{600}$ of 4-5. Bacteria were pelleted at 14000 rpm for 30 min at 4°C and the supernatant was separated from the pellet. The supernatant was consecutively filtered twice with 0.45 µm and 0.22 µm vacuum cellulose acetate filters to completely get rid of the cells. The pellet was washed twice with 250 mL of cold water and then once with 60% cold ethanol, centrifuged each time at 5000 rpm and 4°C and resuspended with vortex. The final clean pellet was resuspended in 100 mL of PBS and the bacteria were killed with 3 flash freeze-thaw cycles with liquid nitrogen/water bath at 60°C, followed by 1 h of incubation with lysozyme (25 µg/mL) on ice. Cells were finally disrupted by sonication using 5 cycles of 30 s at 20 Hz (MSE Soniprep 150), with incubation on ice for 30 s between cycles to avoid overheating. For both the supernatant and the cell lysate, 3 sequential organic extractions with 1:2 ratio of supernatant to dихlorometane (DCM) and 1:10 of cell lysate and DCM were performed, respectively. The organic phases were dried separately to fully remove the DCM using an EZ-2 Elite personal evaporator (GeneVac), in the very low BP mode. The evaporator was maintained at 40°C throughout the process and 15 mL glass tubes rinsed clean with DCM were used for concentrating the organic phase. The final dry extracts were resuspended in 1 mL of ethyl acetate with vortex and kept it at −80°C afterward. Since we started with 1L of material, both extracts were considered to be 1000x concentrated. Appropriate dilutions from the concentrated stock were prepared in ethyl acetate, mixed in a glass falcon tube with 100 µl of water and spread on the top of E. coli seeded 35 mm plates. Ethyl acetate alone was added to E. coli as a vehicle-only control.

Nitric Oxide (NO) experiments
Freshly prepared NGM agar plates were placed open in a tissue culture hood for 30 min to dry and facilitate rapid absorption. Next, 50 µL of 2x OD$_{600}$ = 1 bacterial culture was spread atop the plate, and then a freshly prepared solution of 200 mM NO donor MAHMA NONOate (Sigma) in water was applied to NGM agar plates to achieve a final concentration of 2 mM, and 4 mM. Immediately afterward, ~70 synchronized L1s worms were quickly transferred to the plate.

This protocol was shown to be efficient to extend C. elegans lifespan, even though MAHMA NONOate has a very short half-life at pH 6 (~1 min) (Gusarov et al., 2013). For control experiments, the NO donor was substituted with an equal amount of distilled water. For measurements of the effect of NO on α-synuclein aggregation, worms were moved to freshly prepared NO plates every day starting from L1 and scored at day 1 and 3 of adulthood.

Quantification of aggregation
NLS901 pklr2386[punc-54::α-synuclein::YFP + unc-119(+)] worms were anaesthetized using 50 mM Levamisole (Sigma) and high magnification (40x objective) z stack images of the head region were obtained by using a Zeiss Axio imager 2 microscope. Fluorescent spots bigger than 1 µm$^2$, present in the region between the tip of head and the end of the pharyngeal bulb, were quantified manually, assisted by the Fiji analyze particle function applied to maximum intensity projections of the z stacks. To do so, background subtraction (rolling ball radius of 10 pixels) and adjustment of the threshold (automatic) were applied to the images before the analysis of the number of particles. The total area of the aggregates was extracted from the particle analysis with Fiji and the mean aggregates size per diet was simply calculated considering the total number of aggregates in the corresponding area. 72 hours after plating of the L1s was counted as day 1 adult. At least 25 worms were quantified per time point per condition. Each experiment was performed in triplicate, unless stated otherwise.

Locomotion analysis
Thrashing assays were performed as described before (Pujols et al., 2018), with some modifications. C. elegans NLS901 worms were synchronized as described above and were cultured at 20°C on E. coli OP50 strain until they reached L4 developmental stage. They were then either remained on OP50 diet or transferred to B. subtilis PXN21 (regular 3 days seeded protocol). Thrashing was assayed on days 1, 3, 5, 7 and 10 of adulthood. 5 animals were placed in a 40 µl drop of M9 buffer on an unseeded plate. Movies of thrashing worms were recorded for 3 min using the WormLab tracking platform (MBF Biosciences) at 7.5 frames/second. Waves per minute were obtained by analyzing the last minute of each video (allowing the animals to recover for 120 s after picking them into the drop).
Average frequencies were determined every 0.4 s. Experiments were performed in duplicate. 10 videos per condition and 5 animals per video were analyzed (a total of 100 worms per condition).

**Lifespan assays**

Lifespan assays were performed at 20°C as previously described with modifications (Greer et al., 2007). Briefly, 200-250 synchronized L1s were placed on to corresponding food conditions and were, starting at d1Ad, transferred every 2 days onto fresh food and assessed for survival. Worms that failed to respond to the transfer process and repeated gentle prodding were declared dead and removed. Individuals that were missing or needed to be removed due to internal hatching were marked as censored. Experiments were performed in triplicate.

**Quantification of life-traits**

To determine developmental growth rates, 40-65 worms were mounted on a 3% w/v agarose pad in a drop of 50 mM levamisole and their developmental stages were assessed under compound microscope (DIC, 40X magnification) at exactly 48 h, 60 h, and 72 h after the synchronized L1s were placed on food. Individuals were staged as early L4, late L4, or adult by using the 9 stages of vulva development as reference points as described before (Mok et al., 2015). Stages L4.1 to L4.4 were considered as early L4, L4.5 to L4.9 considered as late L4 and young adult category was based on a fully formed vulva. For size measurements, worms were photographed at 10X and the images analyzed using Fiji (ImageJ). A segmented line was drawn along the center line of each the worm, quantified with the measure function, and then calibrated based on the scale bar. To assess the egg-laying rate and brood size, L4 worms were singled on to 10 separate plates per condition and transferred every 24 hours on to fresh plates until day 5 adult. The numbers of progeny resulting from each day of egg-laying were counted 2 days later.

**Immunoblot analysis**

Day 1 adult worms (~400) were rinsed with M9 + 0.01% Triton X-100, washed 3 times to remove bacteria, pelleted and resuspended in 400 µL of HEPES-based detergent buffer (50 mM HEPES pH 8, 0.2% v/v Triton x 100, 150 mM NaCl, 10 mM NaF, 5 mM DTT) + 1x Protease Inhibitor Mix (GE Healthcare 80-6501-23). Worms were centrifuged at 14000 rpm for 1 min, flash freeze-thawed 5 times with liquid nitrogen/water bath at 80°C and kept at −80°C. Worm pellets were disrupted mechanically using a TissueLyser II (QIAGEN) for 4 cycles of 40 s at 30 Hz, with 200ul of 0.7mm zirconia beads (Biospec). The lysates were centrifuged at 14000 rpm for 1 min and total amount of protein was quantified by Bradford assay (Bio-Rad). NuPAGE (4%–12%) Bis-Tris-gels (Invitrogen) were used to analyze α-synuclein (from 3 µg total protein) and β-actin (from 20 µg total protein) under denaturing conditions as previously described (Landré et al., 2017). Following transfer to nitrocellulose (PALL), membranes intended for α-synuclein analysis were fixed for 10 min using 4% PFA and washed 3 times with PBS containing 0.1% v/v tween-20 prior to blocking. The immunoblots were probed using anti-α-synuclein monoclonal antibody (BD Biosciences) 1:2000 and anti-β-actin (Sigma) 1:500 with appropriate HRP-labeled secondary antibodies (DAKO) at 1:2000. Bound antibodies where detected using ECL.

For the blot corresponding to the time course experiments, 50 worms (in duplicates) from day 1, day 3, day 5, day 7 and day 10 adults in the different diets were manually picked into 50 µl of M9 + 0.01% Triton X-100, washed 3 times to remove bacteria and resuspended in 4xLDS sample buffer supplemented with 10 mM dithiothreitol. Worms were flash freeze on dry ice, sonicated at 4°C for 10 cycles of 40 s at intensity II (Bioruptor® Plus) and boiled at 95°C for 10 min. The lysates were centrifuged at 14000 rpm for 1 min and around 2.5 µl of samples from day 1 adults to day 10 adults were loaded in NuPAGE (4%–12%) Bis-Tris-gels (Invitrogen) and transfer to nitrocellulose (PALL). Membranes were probed with 1:6000 of anti-β-tubulin monoclonal antibody (Sigma) to adjust the volumes manually. Tubulin was specifically selected for these blots because of the higher sensitivity versus actin for samples with low protein content. A second blot was performed by using the previously adjusted volumes for the samples and probed with both 1:6000 of the anti-β-tubulin antibody and 1:2000 of the anti-α-synuclein antibody.

Native protein analysis was carried out using NativePAGE 4%–16% Bis-Tris-gels (Invitrogen) loaded with 30 µg total protein in 1x NativePAGE sample buffer (Invitrogen) containing 0.5% w/v Coomassie Brilliant Blue G-250 per lane. The gel was run at 150V for 2 hours in 1x NativePAGE running buffer (minus G-250; Invitrogen). Proteins where subsequently transferred to nitrocellulose and α-synuclein was detected as described above.

**Nematode RNA Sequencing**

2000 young adult worms (approximately 50–55h after plating of the L1s) grown on E. coli OP50, B. subtilis PXN21 or a 1:1 mix of E. coli: B. subtilis, were collected and washed three times with M9 + 0.01% Triton X-100 buffer. The pellet was resuspended in 400 µl of RNA Lysis buffer (Quick-RNA MicroPrep Kit, Zymo Research) and worms were mechanically disrupted as previously described and kept at −80°C. Total RNA was extracted from the samples according to the manufacturer’s instructions. Three independent biological replicates were used for each experimental condition.

RNA samples were sent to Edinburgh Genomics for QC check and sequencing. Briefly, quality check of the samples was performed using Qubit with the broad range RNA kit (Thermo Fisher Scientific) and Tapestation 4200 with the RNA ScreenTape for eukaryotic RNA analysis (Agilent). Libraries were prepared from 5 µg of total RNA using the TruSeq Stranded mRNA kit (Illumina), and then validated. Samples were pooled to create 9 multiplexed DNA libraries, which were paired-end sequenced on an Illumina HiSeq 4000 platform. At least 290M + 290M 75 nt PE reads were obtained (one lane).
Sequence reads were trimmed using Cutadapt (version cutadapt-1.9.dev2; Martin, 2011) for quality at the 3' end using a quality threshold of 30 and for adaptor sequences of the TruSeq stranded mRNA kit (AGATCGGAAGAGC), with a minimum length of 50. After trimming, reads were aligned against the C. elegans (WBcel235_ens8) genome from Ensembl release 84 with STAR (version 2.5.2b; Dobin et al., 2013) with default parameters, except for specifying paired-end reads and the option “--outSAMtype BAM Unsorted.” Count tables for the different feature levels were obtained from bam files using the featureCounts (Liao et al., 2014) package version 1.5.3 with custom R scripts. Strandness was set to ‘reverse’ and a minimum alignment quality of 10 was specified. Gene names and other fields were derived from input annotation and added to the count/expression matrices. Count tables at the gene level presented a good correlation overall between replicates and samples.

Differential gene expression analysis was conducted for 17,708 genes whose expression was above a minimum “counts per million” (CPM) threshold (CPM 0.1) in at least three samples. Differential gene expression was estimated using the edgeR package (Lun et al., 2016; Robinson et al., 2010) version 3.16.5 and resulting p values were adjusted using a false discovery rate (FDR) criterion. Genes with p values lower than 0.05, FDR values lower than 0.05 and a log2 fold change > 0.58 were considered to be differentially expressed. Heatmaps were generated using R with the heatmap package (Kolde, 2015) (R package version 1.0.8.) or MeV (Multiple Experiment Viewer) version 4.9.0_r2731 (Howe et al., 2010).

Differential gene set analysis was carried out with the ROAST method (Wu et al., 2010) from the Limma package (version 3.30.13; Ritchie et al., 2015) of Bioconductor, using the same models and contrasts as used in differential expression. The following gene sets were used: Gene Ontology Biological Process, Molecular Function and Cellular Component downloaded from Ensembl version 91 (Ashburner et al., 2000; Subramanian et al., 2005); Reactome Pathways (Croft et al., 2014) (Reactome, downloaded January 2018). ROAST was executed using 9,999 rotations (randomizations). Each gene set was annotated with those genes individually differential (in the same direction as indicated for the gene set) to an unadjusted p value of 0.05. KEGG pathways were visualized utilizing the pathview package (Luo and Brouwer, 2013) version 1.24.0 of Bioconductor.

**Reverse transcription and quantitative real-time PCR (qRT-PCR)**

For quantitative real time PCR, 3 μg of total RNA and poly-T(V) (20 nt long) and random hexamers (6 nt long) were used for cDNA synthesis using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) and following manufacturer’s instructions. Quantitative PCR analyses were performed with 1:50 dilutions of the cDNAs using LightCycler 480 SYBR Green I Master mix and a LightCycler 480 II (Roche), following manufacturer’s instructions. Expression of all the genes was normalized to the geometric mean of cdc-42 and F25B5.5 references genes. Expression of these genes was not variable between E. coli and B. subtilis in the RNaseq results. Data was analyzed by using the standard curve method and normalized to E. coli or E. coli arginine samples, respectively. For primer sequences see Table S9, all the primers were ordered from Sigma.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

All assays were performed in triplicate, unless stated otherwise. Graphs and statistical analysis were performed using Graphpad Prism 7. Data shown are presented as mean ± SEM. Statistical significance was calculated by unpaired t test, one-way or two-way ANOVA and Bonferroni multiple comparisons post hoc test, with p < 0.05 considered statistically significant. Statistical significance levels are denoted as follows: ****p < 0.0001; ***p < 0.001; **p < 0.01 and *p < 0.05. All statistical tests were two tailed where applicable.

For the expression levels by qRT-PCR, 3 independent biological samples with technical triplicates were analyzed by using two-way ANOVA with Bonferroni’s post hoc test of logNRQ. ImageJ and Fiji were used to quantify the number and size of the aggregates as described above.

For the lifespan assay, Kaplan-Meier survival curves were generated using the statistical analysis software Graphpad Prism 7. Comparisons were made using the Log-rank (Mantel-Cox) test in both Graphpad Prism 7 and the online survival analysis tool OASIS 2 (Han et al., 2016).

For the immunoblots, quantification of the signals was performed using the gel analysis function of ImageJ and α-synuclein intensity was normalized against β-actin/tubulin signals.

Locomotor analysis was performed using WormLab tracking platform and software (MBF Biosciences).

**DATA AND CODE AVAILABILITY**

The accession number for the C. elegans RNA sequencing data reported in this paper is ArrayExpress: E-MTAB-8164.

The authors declare that all data supporting the findings of this study are available within the article and its Supplementary Information files or upon request.

Code is also available either online where indicated or upon request.